Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks

Inclusion Criteria: * Female, age 18-70 years. * Completed radical breast cancer surgery with confirmed pathology suggested primary invasive breast adenocarcinoma, ER and/or PR positive (defined as positive cells \>1%) and HER2 negative (defined as HER2 immunohistochemistry 2+ or less and FISH negative). * Definition of high-risk factors: 4 or more positive axillary lymph nodes; 1-3 positive axillary lymph nodes with primary tumor ≥ 5 cm or histologic grade 3 or ki67 ≥ 20%; or residual lesions despite neoadjuvant chemotherapy. * No prior treatment for present breast cancer onset. * ECOG physical status score 0 to 1 * Hematological examination before treatment should meet: white blood cell count (WBC) ≥ 4.0×10\^9/L, neutrophil count (ANC) ≥ 1.5×10\^9/L, platelet count (PLT) ≥ 100×10\^9/L; hemoglobin (Hb) ≥ 90g/L; AST (sGOT), ALT (sGPT) ≤ 1.5 times the normal value upper limit, creatinine ≤ 1.5 times the upper limit of normal value, total bilirubin ≤ 1.5 times the upper limit of normal value. * No serious impairment of heart, liver, kidney and other important organ functions. Exclusion Criteria: * Unwilling or unable to use an acceptable method of contraception for up to and including 8 weeks after the final dose of the test drug. * Women during pregnancy and breastfeeding after pregnancy. * Women with proven distant metastases of breast cancer. * Patients with proven sensory or motor nerve disease. * Definite cardiovascular disease, severe co-morbidity or active infection, including known HIV infection. * Patients who need long-term anticoagulant drugs for cardiovascular or thrombotic diseases. * History of other tumors. * Allergic to the study drug or its excipients, etc.